Article
Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2.
Scientific reports - 4 May 2017
Brijwani Nilesh, Jain Misti, Dhandapani Muthu, Zahed Farrah, Mukhopadhyay Pragnashree, Biswas Manjusha, Khatri Deepak, Radhakrishna Vinod D, Majumder Biswanath, Radhakrishnan Padhma, Thiyagarajan Saravanan
Abstract excerpt
KRAS mutation status can distinguish between metastatic colorectal carcinoma (mCRC) patients who may benefit from therapies that target the epidermal growth factor receptor (EGFR), such as cetuximab. However, patients whose tumors harbor mutant KRAS (codons 12/13, 61 and 146) are often excluded from EGFR-targeted regimens, while other patients with wild type KRAS will sometimes respond favorably to these same...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.